Showing 7031-7040 of 8826 results for "".
- Icotrokinra Maintains Psoriasis Responses With Continuous Treatmenthttps://practicaldermatology.com/news/icotrokinra-maintains-psoriasis-responses-with-continuous-treatment/2485554/Continuous treatment with icotrokinra resulted in durable psoriasis control through one year, while treatment withdrawal was associated with rapid loss of response, according to “Maintenance of Response With Icotrokinra for the Treatment of Moderate-to-Severe Plaque Psoriasis: Results From the Ph
- Envudeucitinib Enables Durable Treat-to-Target Control in Plaque Psoriasishttps://practicaldermatology.com/news/envudeucitinib-enables-durable-treat-to-target-control-in-plaque-psoriasis/2485542/Envudeucitinib enabled a high proportion of patients with moderate-to-severe plaque psoriasis to achieve and maintain stringent treat-to-target thresholds through one year of therapy, according to “Achievement of Treat-to-Target Thresholds With Envudeucitinib in Moderate-to-Severe Plaque Psoriasi
- Drs. Neal Bhatia and Ted Rosen Present New Therapeutics ‘Popping’ in 2026https://practicaldermatology.com/news/drs-neal-bhatia-and-ted-rosen-present-new-therapeutics-popping-in-2026/2485511/In their annual overview of therapeutics at Maui Derm Hawaii 2026, Ted Rosen, MD, and Neal Bhatia, MD, used a K-Pop Demon Hunters theme to walk through emerging strategies across inflammatory skin diseases. Drs. Rosen and Bhatia emphasized a shift toward non‑steroidal topicals that can be
- Arcutis Ends Kowa Promotional Partnership, Assumes Control of ZORYVE Promotionshttps://practicaldermatology.com/news/arcutis-ends-kowa-deal-assumes-full-control-of-zoryve-outreach/2485454/Arcutis Biotherapeutics has terminated its co-promotion agreement with Kowa Pharmaceuticals America, Inc. for ZORYVE® (roflumilast), effective January 23, 2026, according to a press relase from the company. Under the prior arran
- Rapid Regrowth Tops Treatment Goals for Alopecia Areata: Surveyhttps://practicaldermatology.com/news/rapid-regrowth-tops-treatment-goals-for-alopecia-areata-survey-finds/2485419/Results from a new national survey presented at the 2026 Winter Clinical Dermatology Hawaii reveals that most US clinicians prioritize rapid and nearly complete hair regrowth, with strong satisfaction reported for Janus kinase (JAK) inhibitor therapies.
- New Data Show BMI Influences Psoriasis Severity and Systemic Inflammationhttps://practicaldermatology.com/news/new-data-show-bmi-influences-psoriasis-severity-and-systemic-inflammation/2485411/Obesity and overweight status were associated with higher baseline prevalence of cardiometabolic comorbidities, psoriatic arthritis (PsA), and systemic inflammation compared to individuals with normal BMI, according to new data from a poster at 2026 Winter Clinical
- No New Safety Signals in Broad Ruxolitinib Dataset, Including AD, Vitiligo, and AAhttps://practicaldermatology.com/news/no-new-safety-signals-in-broad-ruxolitinib-dataset-including-ad-vitiligo-and-aa/2485382/A new safety analysis presented at the 2026 Winter Clinical Dermatology Conference in Maui supporting the long-term tolerability of ruxolitinib cream (Opzelura®, Incyte) in a range of inflammatory skin conditions. The integrat
- Study: Upadacitinib Reduces Inflammation Markers in ADhttps://practicaldermatology.com/news/study-upadacitinib-reduces-inflammation-markers-in-ad/2485380/Upadacitinib (UPA) treatment was associated with significant reductions in biomarkers of systemic inflammation in adults with moderate-to-severe atopic dermatitis (AD), according to a poster presented at Winter Clinical 2026 in Hawaii.
- Dr. April Armstrong Previews New Era for Oral Psoriasis Treatmentshttps://practicaldermatology.com/news/dr-april-armstrong-previews-new-era-for-oral-psoriasis-treatments/2485362/From wild chickens roaming Maui to a growing flock of groundbreaking psoriasis therapies, April W. Armstrong, MD, MPH, delivered an optimistic update on the future of plaque psoriasis treatment during a presentation at the 2026 Winter Clinical Dermatology Conference in Hawaii. “Psoriasis d
- Analysis: CHL-Fe-based PDT Shows Activity Against Drug-Resistant C. acneshttps://practicaldermatology.com/news/chl-febased-photodynamic-therapy-shows-potent-activity-against-drug-resistant-c-acnes/2485327/Photodynamic therapy (PDT) using sodium iron chlorophyllin (CHL-Fe) and red light achieved consistent bactericidal effects against drug-resistant Cutibacterium acnes (C. acnes) strains in vitro, according to new study finding